Literature DB >> 17284133

Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia.

Anne Karow1, Joerg Czekalla, Ralf W Dittmann, Alexander Schacht, Thomas Wagner, Martin Lambert, Benno G Schimmelmann, Dieter Naber.   

Abstract

OBJECTIVE: Subjective well-being is considered important for compliance with antipsychotic treatment. The objective of this post hoc analysis of data from German patients in the Schizophrenia Outpatient Health Outcomes study was to investigate subjective well-being and compliance, with consideration of clinical symptoms and side effects, in outpatients diagnosed with schizophrenia.
METHOD: In a multicenter observational study of 2960 patients with DSM-IV-defined schizophrenia recruited between January and December 2001, subjective well-being was measured during 12 months with the Subjective Well-Being Under Neuroleptic Treatment Scale, short version (SWN-K). Compliance was self- and physician-rated. The association of compliance with clinical parameters was assessed by logistic regression.
RESULTS: Factor analysis resulted in 3 factors: SWN-K (r2 = 0.867), clinical symptoms (r2 = 0.744), and side effects (r2 = 0.420). The odds for being compliant were 1.363 times higher if the SWN-K score increased by 20 points. Changes in positive symptoms (OR = 0.773) and changes in extrapyramidal symptoms (OR = 0.830) were found to be associated with compliance.
CONCLUSION: Compliance with antipsychotic medication was strongly associated with subjective well-being; further factors were clinical symptoms and side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17284133     DOI: 10.4088/jcp.v68n0110

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  28 in total

1.  Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility.

Authors:  Meike Kasten; Norbert Brüggemann; Inke R König; Katja Doerry; Susanne Steinlechner; Liv Wenzel; Katja Lohmann; Christine Klein; Rebekka Lencer
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

Review 2.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

3.  Should we listen and talk more to our patients?

Authors:  Dieter Naber; Martin Lambert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

4.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

5.  The predictive validity of subjective adherence measures in patients with schizophrenia.

Authors:  Martijn J Kikkert; Maarten W J Koeter; Jack J M Dekker; Lorenzo Burti; Debbie Robson; Bernd Puschner; Aart H Schene
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

6.  A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.

Authors:  Seung Jae Lee; Jong Hun Lee; Sung Won Jung; Bon Hoon Koo; Tae Young Choi; Kwang Hun Lee
Journal:  Clin Drug Investig       Date:  2012-11       Impact factor: 2.859

7.  Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis.

Authors:  Steffen Moritz; Jerome Favrod; Christina Andreou; Anthony P Morrison; Francesca Bohn; Ruth Veckenstedt; Peter Tonn; Anne Karow
Journal:  Schizophr Bull       Date:  2012-02-15       Impact factor: 9.306

8.  The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life.

Authors:  A Karow; F-G Pajonk; J Reimer; F Hirdes; C Osterwald; D Naber; S Moritz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

9.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07

10.  Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia.

Authors:  Hong Liu-Seifert; David H Adams; Haya Ascher-Svanum; Douglas E Faries; Bruce J Kinon
Journal:  Patient Prefer Adherence       Date:  2007-12-20       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.